Compare · NUVA vs RMD
NUVA vs RMD
Side-by-side comparison of NuVasive Inc. (NUVA) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NUVA and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD carries a market cap of $33.14B.
- RMD has hit the wire 26 times in the past 4 weeks while NUVA has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 18 for NUVA).
- Company
- NuVasive Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- -
- $33.14B
- 1M return
- -
- -6.86%
- 1Y return
- -
- -5.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 0
- 26
- Recent ratings
- 18
- 25
NuVasive Inc.
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process. In addition, it provides MAGEC, a spinal bracing and distraction system, Precice limb lengthening system, and various other products for treating specialized orthopedic procedures; onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries; and cervical artificial disc technology for cervical total disc replacement procedures. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NUVA
- SEC Form 15-12G filed by NuVasive Inc.
- SEC Form SC 13G/A filed by NuVasive Inc. (Amendment)
- SEC Form EFFECT filed by NuVasive Inc.
- SEC Form EFFECT filed by NuVasive Inc.
- SEC Form EFFECT filed by NuVasive Inc.
- SEC Form EFFECT filed by NuVasive Inc.
- SEC Form EFFECT filed by NuVasive Inc.
- SEC Form EFFECT filed by NuVasive Inc.
- SEC Form 4 filed by Wolterman Dan
- SEC Form 4 filed by Raimundo Amy Belt
Latest RMD
- Chairman and CEO Michael J. Farrell was granted 48,136 units of ResMed Common Stock and covered exercise/tax liability with 28,180 units of ResMed Common Stock, increasing direct ownership by 4% to 491,729 units (SEC Form 4) to satisfy withholding obligation
- Director Christopher Delorefice was granted 554 units of ResMed Common Stock, increasing direct ownership by 23% to 2,977 units (SEC Form 4)
- Global General Counsel Michael J Rider was granted 5,587 units of ResMed Common Stock and covered exercise/tax liability with 3,084 units of ResMed Common Stock, increasing direct ownership by 24% to 12,919 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Ronald R Taylor
- Director Harjit Gill was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 12,013 units (SEC Form 4)
- Director Desney Tan was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 18% to 7,111 units (SEC Form 4)
- Director John Hernandez was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 22% to 6,227 units (SEC Form 4)
- Director Karen Drexler was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 11,711 units (SEC Form 4)
- Chief Product Officer Justin Leong was granted 10,314 units of ResMed Common Stock (SEC Form 4)
- Director Carol Burt was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 51% to 3,265 units (SEC Form 4)